ArticleFrontiers in psychiatry2025
The impact of chronic stress on cortical thickness in patients with depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Morphological, Histological and Ultrastructural Characterization of the Common Dolphin's Adrenal Glands.Veterinary sciences · 2026Article
- Prenatal antidepressant exposure is associated withFrontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effect of chronic stress on cortical thickness in patients with depression. Methods: We recruited 90 participants (Jan 2023-Oct 2024): 30 treatment-naive depressed patients with chronic stress (CSD group; mean age 39.1 ± 9.8 years, baseline HAMD-17 27.4 ± 4.8), 30 treatment-naive depressed patients without chronic stress (Dep group; 38.9 ± 9.6 years, HAMD 26.1 ± 4.9), and 30 age/sex-matched healthy controls (HC; 41.2 ± 10.0 years). Chronic stress was defined using the Life Events Scale (LES > 100, based on regional norms). All patients received Fluvoxamine Maleate treatment. LES scores, HAMD-17 scores, and cortical thickness (via MRI) were assessed pre-treatment and 2 months post-treatment. Depressive relapse was monitored for 12-14 months (mean 12.9 ± 1.6 months). Results: Baseline: LES scores were CSD > Dep > HC (all P<0.05); HAMD scores were CSD≈Dep > HC (P<0.05). Compared to HC, both patient groups showed reduced baseline cortical thickness in left pars triangularis, pars opercularis, precuneus, middle temporal, and cingulate gyri, and right superior frontal, precuneus, and inferior frontal gyri (P<0.05). Crucially, the CSD group exhibited significantly greater thinning than the Dep group in these regions (P<0.05). Post-treatment (2 months): LES and HAMD scores decreased significantly in both patient groups but remained higher than HC (P<0.05). Post-treatment LES scores remained CSD > Dep (P<0.05), while HAMD scores were similar between patient groups (P>0.05). Cortical thickness increased in CSD and Dep groups but did not reach HC levels (P<0.05), and the difference between CSD and Dep thickness was no longer significant (P>0.05). The CSD group experienced significantly faster time to relapse (mean 5.4 ± 2.3 months) compared to the Dep group (8.3 ± 2.5 months; t=4.656, P<0.001). Conclusion: Chronic stress contributes to greater cortical thinning in depressed patients, particularly in specific frontal, temporal, parietal, and cingulate regions. Although treatment facilitates cortical thickness recovery alongside symptom improvement, individuals experiencing chronic stress relapse more quickly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.